{"url_path":"/sec/cldi/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1855485/0001493152-26-023140-index.html","accession_number":"0001493152-26-023140","cik":"0001855485","ticker":"CLDI","issuer_name":"Calidi Biotherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1855485/0001493152-26-023140-index.html","primary_entity_key":"0001855485","primary_entity_name":"Calidi Biotherapeutics, Inc."},"word_count":447,"has_tables":true,"body_markdown":"**Item\n6. Exhibits.**\n\n \n\n**EXHIBIT\nINDEX**\n\n \n\n**Exhibit**\n\n**No.**\n\n \n**Description**\n\n4.1\n \n[Form of Pre-funded Warrant (incorporated herein by reference to Exhibit 4.1 to Form 8-K filed with the SEC on March 11, 2026).](https://www.sec.gov/Archives/edgar/data/1855485/000149315226009701/ex4-1.htm)\n\n \n \n \n\n4.2\n \n[Form of Series J Common Warrant (incorporated herein by reference to Exhibit 4.2 to Form 8-K filed with the SEC on March 11, 2026).](http://www.sec.gov/Archives/edgar/data/1855485/000149315226009701/ex4-2.htm)\n\n \n \n \n\n4.3\n \n[Form of Series K Common Warrant (incorporated herein by reference to Exhibit 4.3 to Form 8-K filed with the SEC on March 11, 2026).](https://www.sec.gov/Archives/edgar/data/1855485/000149315226009701/ex4-3.htm)\n\n \n \n \n\n4.4\n \n[Form of Series L Common Warrant (incorporated herein by reference to Exhibit 4.4 to Form 8-K filed with the SEC on March 11, 2026).](https://www.sec.gov/Archives/edgar/data/1855485/000149315226009701/ex4-4.htm)\n\n \n \n \n\n4.5\n \n[Form of Series Representative Warrant (incorporated herein by reference to Exhibit 4.5 to Form 8-K filed with the SEC on March 11, 2026).](https://www.sec.gov/Archives/edgar/data/1855485/000149315226009701/ex4-5.htm)\n\n \n \n \n\n4.6\n \n[Form of Warrant Amendment (incorporated herein by reference to Exhibit 4.6 to Form 8-K filed with the SEC on March 11, 2026).](https://www.sec.gov/Archives/edgar/data/1855485/000149315226009701/ex4-6.htm)\n\n \n \n \n\n10.1\n \n[Underwriting Agreement, dated March 6, 2026 (incorporated herein by reference to Exhibit 1.1 to Form 8-K filed with the SEC on March 11, 2026).](https://www.sec.gov/Archives/edgar/data/1855485/000149315226009701/ex1-1.htm)\n\n \n \n \n\n10.2\n \n[Form of Warrant Agency Agreement (incorporated herein by reference to Exhibit 10.1 to Form 8-K filed with the SEC on March 11, 2026).](https://www.sec.gov/Archives/edgar/data/1855485/000149315226009701/ex10-1.htm)\n\n \n \n \n\n31.1*\n \n[Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex31-1.htm)\n\n \n \n \n\n31.2*\n \n[Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex31-2.htm)\n\n \n \n \n\n32.1**\n \n[Certificate of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32-1.htm)\n\n \n \n \n\n32.2**\n \n[Certificate of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32-2.htm)\n\n \n \n \n\n101.INS\n \nInline\nXBRL Instance Document\n\n \n \n \n\n101.\nSCH\n \nInline\nXBRL Taxonomy Extension Schema Document\n\n \n \n \n\n101.CAL\n \nInline\nXBRL Taxonomy Extension Calculation Linkbase Document.\n\n \n \n \n\n101.DEF\n \nInline\nXBRL Taxonomy Extension Definition Linkbase Document.\n\n \n \n \n\n101.LAB\n \nInline\nXBRL Taxonomy Extension Labels Linkbase Document.\n\n \n \n \n\n101.PRE\n \nInline\nXBRL Taxonomy Extension Presentation Linkbase Document.\n\n \n \n \n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n*\nFiled\nherewith\n\n**\nFurnished\nherewith.\n\n \n\n48\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned thereunto duly authorized.\n\n \n\n \nCalidi\nBiotherapeutics, Inc.\n\n \n \n \n\nDate:\nMay 14, 2026\nBy:\n*/s/\nEric Poma*\n\n \nName:\nEric\nPoma\n\n \nTitle:\n\nChief\nExecutive Officer\n\n*(Principal\nExecutive Officer)*\n\n \n \n \n\nDate:\nMay 14, 2026\nBy:\n*/s/\nAndrew Jackson*\n\n \nName:\n\nAndrew\nJackson\n\n \nTitle:\n\nChief\nFinancial Officer\n\n*(Principal\nFinancial and Accounting Officer)*\n\n \n\n49"}